Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 10/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13674553 | 1.00 | CXCR3 (0.40) | CXCR3NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13675466 | 0.92 | NPC1 (0.41) | CXCR3NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4501678 | 0.92 | FFAR4 (0.36) | CXCR3 | |
| SCHEMBL5547214 | 0.92 | CXCR3 (0.42) | CXCR3NPC1F10POLB | |
| SCHEMBL13674555 | 0.92 | CXCR3 (0.42) | CXCR3NPC1F10POLB | |
| SCHEMBL4519486 | 0.88 | KLKB1 (0.36) | CXCR3NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13674551 | 0.86 | PDK2 (0.42) | — | |
| SCHEMBL4515543 | 0.86 | SLC6A9 (0.41) | SMN1; SMN2 | |
| SCHEMBL13674556 | 0.86 | SLC6A9 (0.41) | SMN1; SMN2 | |
| SCHEMBL4514859 | 0.85 | MAPT (0.40) | RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | CXCR3 3585/4885NPC1 286/4885HPGD 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.